title: Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection.
abstract: To study the cross-reactivity pattern of Shigella flexneri 2a O-antigen antibodies, sera from humans and monkeys challenged with S. flexneri 2a, and from humans and guinea pigs immunized with a recombinant vaccine expressing serotype 2a O-antigen, were tested against a panel of lipopolysaccharide extracted from heterologous S. flexneri. Sera from the two groups of humans, who were volunteers in either a clinical challenge or vaccination study, showed similar patterns: cross-reactivity was more often seen with IgA antibodies, and these were mostly cross-reactive with serotype 2b, which shares the type II antigen, and serotypes 1a, 5a, and Y, which share 4 or 3, 4 group antigen, with 2a. The majority of sera from immunized guinea pigs showed both IgG and IgA cross-reactivity with 1a, 5a, and Y, but not 2b. The majority of sera from challenged monkeys showed cross-reactivity with almost all flexneri serotypes tested, with 1a, 2b, and Y being recognized most often, and the cross-reactive antibodies were more often IgG than IgA. These results show that either immunization or challenge with the 2a serotype induces cross-reactive antibodies which recognize similar subsets of heterologous serotypes, and suggest that it may be possible to design multivalent vaccines against S. flexneri.
authors.affiliation: Department of Enteric Infections, Walter Reed Army Institute of Research, Washington DC 20307-5100, USA.
authors.forename: L L
authors.initials: LL
authors.lastname: Van De Verg
authors.forename: N O
authors.initials: NO
authors.lastname: Bendiuk
authors.forename: K
authors.initials: K
authors.lastname: Kotloff
authors.forename: M M
authors.initials: MM
authors.lastname: Marsh
authors.forename: J L
authors.initials: JL
authors.lastname: Ruckert
authors.forename: J L
authors.initials: JL
authors.lastname: Puryear
authors.forename: D N
authors.initials: DN
authors.lastname: Taylor
authors.forename: A B
authors.initials: AB
authors.lastname: Hartman
mesh_terms: D000328:Adult; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology*; D001428:Bacterial Vaccines / Q000276:immunology*; D002240:Carbohydrate Sequence; D003429:Cross Reactions; D004405:Dysentery, Bacillary / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D006168:Guinea Pigs; D000882:Haplorhini; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008070:Lipopolysaccharides / Q000276:immunology; D008969:Molecular Sequence Data; D019081:O Antigens / Q000276:immunology*; D012763:Shigella flexneri / Q000145:classification* / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D008070:Lipopolysaccharides; D019081:O Antigens; D014614:Vaccines, Synthetic